Cardiome Pharma Corp (NASDAQ:CRME) Stock Price Down as Sentiment Crashes

July 14, 2018 - By Kyle Williams

Sentiment for Cardiome Pharma Corp (NASDAQ:CRME)

Cardiome Pharma Corp (NASDAQ:CRME) institutional sentiment decreased to 0.45 in Q1 2018. Its down -0.01, from 0.46 in 2017Q4. The ratio is negative, as 5 investment professionals started new or increased equity positions, while 11 sold and reduced their positions in Cardiome Pharma Corp. The investment professionals in our partner’s database now possess: 11.38 million shares, down from 12.53 million shares in 2017Q4. Also, the number of investment professionals holding Cardiome Pharma Corp in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 6 Increased: 3 New Position: 2.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $81.10 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

The stock decreased 1.68% or $0.04 during the last trading session, reaching $2.34. About 90,444 shares traded or 54.31% up from the average. Cardiome Pharma Corp. (NASDAQ:CRME) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Clough Capital Partners L P holds 0.46% of its portfolio in Cardiome Pharma Corp. for 2.08 million shares. Rock Springs Capital Management Lp owns 1.20 million shares or 0.12% of their US portfolio. Moreover, Westfield Capital Management Co Lp has 0.07% invested in the company for 4.19 million shares. The Massachusetts-based Putnam Investments Llc has invested 0.02% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 45 shares.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Ratings analysis reveals 100% of Cardiome Pharma Corp’s analysts are positive. Out of 2 Wall Street analysts rating Cardiome Pharma Corp, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.8 while the high is $9.5000. The stock’s average target of $6.15 is 162.82% above today’s ($2.34) share price. CRME was included in 3 notes of analysts from March 14, 2018. Mackie maintained the shares of CRME in report on Wednesday, March 14 with “Buy” rating. H.C. Wainwright maintained Cardiome Pharma Corp. (NASDAQ:CRME) on Thursday, May 17 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, April 4.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.